{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:24:45Z","timestamp":1761863085842},"reference-count":124,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T00:00:00Z","timestamp":1334880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Learning Objectives:<\/jats:title><jats:p>After completing this course, the reader will be able to: Discuss the optimal strategies to treat HER-2+ metastatic breast cancer patients in the first-line setting and after recurrence with adjuvant trastuzumab.Identify the current first-line therapeutic options for HER-2+ metastatic breast cancer, including HER-2\/hormone receptor copositive tumors.Discuss the most important advances for HER-2+ metastatic breast cancer and the potential of novel anti-HER-2 therapies.<\/jats:p><jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p><\/jats:sec><jats:sec><jats:title>Background.<\/jats:title><jats:p>The prognosis for breast cancer patients overexpressing human epidermal growth factor receptor (HER)-2 has changed with anti\u2013HER-2\u2013targeted therapy. Although anti\u2013HER-2 therapy with trastuzumab and chemotherapy is the standard first-line treatment, the best therapeutic regimen has yet to be defined, and new strategies are evolving.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A literature review of well-established and recently published trials, reviews, and ongoing clinical trials addressing first-line treatment for HER-2+ metastatic breast cancer patients was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Taxanes are the agents most commonly used in combination with trastuzumab, but other chemotherapy drugs, such as anthracyclines, vinorelbine, and gemcitabine and triple-combination therapies including platinum compounds, capecitabine, and taxanes have been studied. The combination of aromatase inhibitors with anti\u2013HER-2 therapies is a new therapeutic option for some patients who coexpress HER-2 and hormone receptors, although its activity observed in randomized clinical trials seems to be inferior to that of chemotherapy plus anti\u2013HER-2 therapies. In addition, new anti\u2013HER-2 therapies have shown activity in HER-2+ tumors, both alone and in combination with trastuzumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>Trastuzumab plus chemotherapy is the current standard of care for the upfront treatment of HER-2+ breast cancer patients, though other anti\u2013HER-2\u2013targeting agents may appear as new standards in the upcoming years.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0187","type":"journal-article","created":{"date-parts":[[2012,4,21]],"date-time":"2012-04-21T06:48:47Z","timestamp":1334990927000},"page":"631-644","source":"Crossref","is-referenced-by-count":26,"title":["Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer"],"prefix":"10.1093","volume":"17","author":[{"given":"Leticia","family":"De Mattos-Arruda","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Vall D\u2032Hebron University Hospital, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Vall D\u2032Hebron University Hospital, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,4,20]]},"reference":[{"key":"2021122308234525000_B1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3322\/canjclin.56.3.168","article-title":"Trends in breast cancer by race and ethnicity: Update 2006","volume":"56","author":"Smigal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"2021122308234525000_B2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.12-1-20","article-title":"Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program","volume":"12","author":"Hayat","year":"2007","journal-title":"The Oncologist"},{"key":"2021122308234525000_B3","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2021122308234525000_B5","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdg365","article-title":"Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer","volume":"14","author":"Atalay","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122308234525000_B6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"2021122308234525000_B7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3816\/CBC.2005.n.026","article-title":"Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab","volume":"6","author":"Mass","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"2021122308234525000_B8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122308234525000_B9","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122308234525000_B10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.11-90001-34","article-title":"HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy","volume":"11","author":"Jackisch","year":"2006","journal-title":"The Oncologist"},{"key":"2021122308234525000_B11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2005.01.014","article-title":"Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B14","volume-title":"Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: Patients surviving more than 4 years in the M77001 study","author":"Marty","year":"2006"},{"key":"2021122308234525000_B15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clbc.2011.03.003","article-title":"Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial","volume":"11","author":"Hamberg","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"2021122308234525000_B16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cncr.22885","article-title":"Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study","volume":"110","author":"Burstein","year":"2007","journal-title":"Cancer"},{"key":"2021122308234525000_B17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","article-title":"Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study","volume":"29","author":"Andersson","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B18","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer","volume":"96","author":"Pegram","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122308234525000_B20","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","article-title":"Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer","volume":"24","author":"Robert","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","article-title":"Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens","volume":"29","author":"Valero","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3816\/CBC.2005.n.047","article-title":"Two concurrent phase II trials of paclitaxel\/carboplatin\/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252","volume":"6","author":"Perez","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"2021122308234525000_B23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1081\/CNV-200032980","article-title":"Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)","volume":"22","author":"Fountzilas","year":"2004","journal-title":"Cancer Invest"},{"key":"2021122308234525000_B24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3816\/CBC.2008.n.051","article-title":"A phase II trial of gemcitabine\/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer","volume":"8","author":"Yardley","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"2021122308234525000_B25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2008.21.6531","article-title":"Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer","volume":"28","author":"Wardley","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djm252","article-title":"HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials","volume":"100","author":"Gennari","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2021122308234525000_B27","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122308234525000_B28","doi-asserted-by":"crossref","first-page":"LBA513","DOI":"10.1200\/jco.2007.25.18_suppl.lba513","article-title":"Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin\/cyclophosphamide (AC)\u2192paclitaxel (T) vs. AC\u2192T with trastuzumab(H)","volume":"25","author":"Rastogi","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B30","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122308234525000_B32","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1200\/JCO.2009.23.0946","article-title":"Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial","volume":"27","author":"Spielmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B33","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","article-title":"Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials","volume":"28","author":"Russell","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"2021122308234525000_B35","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122308234525000_B37","first-page":"216","article-title":"TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): Final cardiac safety and efficacy analysis","volume":"21","author":"Theodoulou","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122308234525000_B38","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.ejca.2011.05.005","article-title":"A phase I\/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer","volume":"47","author":"Amadori","year":"2011","journal-title":"Eur J Cancer"},{"key":"2021122308234525000_B39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1158\/1078-0432.CCR-08-1113","article-title":"Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase I\/II study","volume":"15","author":"Cortes","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308234525000_B40","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2005.03.8331","article-title":"Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial","volume":"24","author":"Chia","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-010-0838-7","article-title":"Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198","volume":"121","author":"Wolff","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"18 suppl","key":"2021122308234525000_B42","doi-asserted-by":"crossref","first-page":"10663","DOI":"10.1200\/jco.2006.24.18_suppl.10663","article-title":"Paclitaxel (P), pegylated liposomal doxorubicin (PLD) and trastuzumab as 1st-line chemotherapy (chemo) in HER2\/neu-positive (+) metastatic breast cancer (MBC)","volume":"24","author":"Karabelis","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B43","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"Nahta","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"2021122308234525000_B44","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1158\/1078-0432.CCR-09-3407","article-title":"Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor","volume":"16","author":"Scaltriti","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308234525000_B45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res"},{"key":"2021122308234525000_B46","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ejca.2007.08.018","article-title":"Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer","volume":"43","author":"P\u00e0lyi-Krekk","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122308234525000_B47","doi-asserted-by":"crossref","first-page":"8240","DOI":"10.1158\/0008-5472.CAN-07-0589","article-title":"Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab","volume":"67","author":"Lu","year":"2007","journal-title":"Cancer Res"},{"key":"2021122308234525000_B48","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1038\/sj.emboj.7601191","article-title":"Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation","volume":"25","author":"Anido","year":"2006","journal-title":"EMBO J"},{"key":"2021122308234525000_B49","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122308234525000_B50","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell"},{"key":"2021122308234525000_B51","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","article-title":"Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab","volume":"28","author":"Andre","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-007-9584-x","article-title":"A phase 2 study of perifosine in advanced or metastatic breast cancer","volume":"108","author":"Leighl","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2021122308234525000_B53","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Nahta","year":"2005","journal-title":"Cancer Res"},{"key":"2021122308234525000_B54","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-07-5962","article-title":"Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells","volume":"68","author":"Shattuck","year":"2008","journal-title":"Cancer Res"},{"key":"2021122308234525000_B55","volume-title":"Targeting of the chemokine receptor CXCR4 in acquired trastuzumab resistance","author":"Tripathy","year":"2007"},{"key":"2021122308234525000_B56","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1158\/1078-0432.CCR-05-2663","article-title":"PC cell-derived growth factor stimulates proliferation and confers trastuzumab resistance to Her-2-overexpressing breast cancer cells","volume":"12","author":"Kim","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122308234525000_B57","volume-title":"Increased b1 integrin expression is a predictor of trastuzumab resistance in HER-2 overexpressing metastatic breast cancer patients","author":"Thoms","year":"2007"},{"key":"2021122308234525000_B58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(02)00097-1","article-title":"Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth","volume":"2","author":"Agus","year":"2002","journal-title":"Cancer Cell"},{"key":"2021122308234525000_B59","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B60","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1158\/1078-0432.CCR-08-1978","article-title":"A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors","volume":"15","author":"Wong","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308234525000_B61","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1634\/theoncologist.2009-0142","article-title":"Beyond trastuzumab: Small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer","volume":"14","author":"Roy","year":"2009","journal-title":"The Oncologist"},{"key":"2021122308234525000_B62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"2021122308234525000_B63","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1634\/theoncologist.2011-0165","article-title":"Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2+ metastatic breast cancer","volume":"16","author":"Wong","year":"2011","journal-title":"The Oncologist"},{"key":"2021122308234525000_B64","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.imlet.2005.11.018","article-title":"Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1","volume":"104","author":"Zsebik","year":"2006","journal-title":"Immunol Lett"},{"key":"2021122308234525000_B65","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1158\/1078-0432.CCR-11-0072","article-title":"HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab","volume":"17","author":"Modi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122308234525000_B66","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1023\/B:JOCI.0000040928.67495.52","article-title":"Humoral epitope-spreading following immunization with a HER-2\/neu peptide based vaccine in cancer patients","volume":"24","author":"Disis","year":"2004","journal-title":"J Clin Immunol"},{"key":"2021122308234525000_B67","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1158\/1078-0432.CCR-05-2436","article-title":"Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer","volume":"12","author":"Kiewe","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122308234525000_B68","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122308234525000_B69","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B70","first-page":"971","article-title":"Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, Taxotere, gemcitabine, and epothilone B","volume":"2","author":"Fuino","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"2021122308234525000_B71","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/1535-7163.MCT-06-0104","article-title":"Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner","volume":"5","author":"Cardoso","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"29 suppl","key":"2021122308234525000_B72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/jco.2011.29.15_suppl.507","article-title":"Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial)","author":"Guarneri","year":"2011","journal-title":"J Clin Oncol"},{"issue":"29 suppl","key":"2021122308234525000_B73","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1200\/jco.2011.29.15_suppl.530","article-title":"Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study","author":"Loibl","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B74","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1200\/JCO.2007.14.0590","article-title":"Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer","volume":"26","author":"Gomez","year":"2008","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122308234525000_B75","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/jco.2007.25.18_suppl.1027","article-title":"Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC)","volume":"25","author":"Crown","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B76","volume-title":"Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3 week paclitaxel","author":"Jones","year":"2004"},{"key":"2021122308234525000_B77","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","article-title":"Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells","volume":"66","author":"Konecny","year":"2006","journal-title":"Cancer Res"},{"key":"2021122308234525000_B78","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/onc.2008.432","article-title":"Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity","volume":"28","author":"Scaltriti","year":"2009","journal-title":"Oncogene"},{"key":"2021122308234525000_B79","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122308234525000_B80","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1200\/jco.2010.28.15_suppl.1046","article-title":"Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer","volume":"28","author":"Esteva","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B81","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","article-title":"Quantitative association between HER-2\/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer","volume":"95","author":"Konecny","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021122308234525000_B82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-006-9307-8","article-title":"The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers","volume":"102","author":"Marcom","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"2021122308234525000_B83","doi-asserted-by":"crossref","first-page":"865s","DOI":"10.1158\/1078-0432.865s.11.2","article-title":"Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer","volume":"11","author":"Osborne","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122308234525000_B84","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr Rev"},{"key":"2021122308234525000_B85","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B86","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1634\/theoncologist.2009-0240","article-title":"Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer","volume":"15","author":"Schwartzberg","year":"2011","journal-title":"The Oncologist"},{"key":"2021122308234525000_B87","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B88","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1200\/JCO.2009.23.1910","article-title":"Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated","volume":"28","author":"Leyland-Jones","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B89","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1200\/JCO.2011.36.4091","article-title":"Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: Can there be too many active drugs?","volume":"29","author":"Chandarlapaty","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B90","volume-title":"Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer (NEFERTT)"},{"key":"2021122308234525000_B91","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122308234525000_B92","volume-title":"A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab\/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)"},{"key":"2021122308234525000_B93","volume-title":"Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1)"},{"key":"2021122308234525000_B94","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS11-S4-8","volume-title":"First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent\/metastatic breast cancer (LR\/mBC)","author":"Gianni","year":"2011"},{"key":"2021122308234525000_B95","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","article-title":"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122308234525000_B96","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/jco.2009.27.15_suppl.1023","article-title":"Use of BIBW 2992, a novel irreversible EGFR\/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab","volume":"7","author":"Hickish","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B97","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","article-title":"Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy","volume":"28","author":"Baselga","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B98","volume-title":"Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study (\u2018NeoSphere\u2019)","author":"Gianni","year":"2010"},{"key":"2021122308234525000_B99","volume-title":"First results of the NeoALTTO trial (BIG 01\u201306 \/ EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer","author":"Baselga","year":"2010"},{"key":"2021122308234525000_B100","volume-title":"Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44)","author":"Untch","year":"2010"},{"key":"2021122308234525000_B101","volume-title":"Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: A randomized phase II study (TRYPHAENA)","author":"Schneeweiss","year":"2011"},{"key":"2021122308234525000_B102","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"2021122308234525000_B103","volume-title":"Trastuzumab emtansine (T-DM1) versus trastuzumab + docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g\/BO21976) [abstract 5.001]","author":"Hurvitz","year":"2011"},{"key":"2021122308234525000_B104","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"issue":"15 suppl","key":"2021122308234525000_B105","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/jco.2010.28.15_suppl.1013","article-title":"Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial","volume":"28","author":"Dalenc","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B106","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","article-title":"Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy","volume":"29","author":"Morrow","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B107","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1158\/1078-0432.CCR-0951-3","article-title":"Association between HER-2\/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients","volume":"10","author":"Konecny","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122308234525000_B108","doi-asserted-by":"crossref","volume-title":"Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer","author":"Hurvitz","DOI":"10.1158\/0008-5472.SABCS-09-6094"},{"key":"2021122308234525000_B109","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122308234525000_B110","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","article-title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial","volume":"12","author":"Gianni","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308234525000_B111","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B112","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6602738","article-title":"Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease","volume":"93","author":"Zidan","year":"2005","journal-title":"Br J Cancer"},{"key":"2021122308234525000_B113","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/cncr.20987","article-title":"Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma","volume":"103","author":"Gong","year":"2005","journal-title":"Cancer"},{"key":"2021122308234525000_B114","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ijc.23051","article-title":"HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy","volume":"122","author":"Santinelli","year":"2008","journal-title":"Int J Cancer"},{"key":"2021122308234525000_B115","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1634\/theoncologist.2008-0048","article-title":"Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management","volume":"13","author":"Guarneri","year":"2008","journal-title":"The Oncologist"},{"key":"2021122308234525000_B116","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/bjc.2011.89","article-title":"Detection of HER2 amplification in circulating free DNA in patients with breast cancer","volume":"104","author":"Page","year":"2011","journal-title":"Br J Cancer"},{"key":"2021122308234525000_B117","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/14656566.2011.525218","article-title":"Hitting multiple targets in HER2-positive breast cancer: Proof of principle or therapeutic opportunity?","volume":"12","author":"Geuna","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"suppl 1","key":"2021122308234525000_B118","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1517\/13543781003730135","article-title":"Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy\u2014current evidence and future trends","volume":"19","author":"Metzger-Filho","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"2021122308234525000_B119","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122308234525000_B120","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26\/Breast International Group 03\u201305 study","volume":"27","author":"Minckwitz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B121","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1200\/JCO.2009.23.8089","article-title":"How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer","volume":"27","author":"Cortes","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308234525000_B122","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrclinonc.2010.185","article-title":"HER2 and hormone receptor-positive breast cancer\u2014blocking the right target","volume":"8","author":"Cort\u00e9s","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122308234525000_B123","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/annonc\/mdr061","article-title":"Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer","volume":"23","author":"Olson","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122308234525000_B124","article-title":"Retreatment with trastuzumab-based therapy after disease progression following lapatinib in her2-positive metastatic breast cancer","author":"Gori","year":"2011","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0187","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/5\/631\/41860112\/oncolo_17_5_631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/5\/631\/41860112\/oncolo_17_5_631.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T16:16:44Z","timestamp":1713889004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/5\/631\/6403367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,20]]},"references-count":124,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,4,20]]},"published-print":{"date-parts":[[2012,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0187","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,5,1]]},"published":{"date-parts":[[2012,4,20]]}}}